search
Back to results

Clinical Evaluation of Removing Blood Stasis Therapy in Treating Acute Cerebral Hemorrhage Safety and Efficacy (CERBSTTSCH)

Primary Purpose

Intracerebral Hemorrhage, Hypertensive, Traditional Chinese Medicine

Status
Unknown status
Phase
Phase 4
Locations
China
Study Type
Interventional
Intervention
AICH-PXZY
AICH-without PXZY
AICH-placebo
Sponsored by
Guangzhou University of Traditional Chinese Medicine
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Intracerebral Hemorrhage, Hypertensive focused on measuring Blood-breaking Decotion

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Greater than or equal to 18 years old while younger than 80 years old
  • acute cerebral hemorrhage confirmed by brain CT scan within 6 to72 hours from onset
  • GCS≥6
  • Sign the informed consent form

Exclusion Criteria:

  • Tests have confirmed that cerebral hemorrhage caused by brain tumor, blood diseases, cerebrovascular malformation (anomaly) or aneurysm, etc;
  • patients with Severe heart, liver and renal insufficiency.
  • Intolerance to traditional Chinese medicine (TCM), allergic constitution.
  • patients with severe cerebral hernia in the early onset
  • Compliance is poor.

Sites / Locations

  • Guangdong Provincial Science and Technology Agency
  • Guangdong Provincial Hospital of Chinese Medicine

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Placebo Comparator

Arm Label

Experimental: AICH-PXZY

Experimental: AICH-without PXZY

Placebo: AICH-placebo

Arm Description

Removing Blood Stasis medicine with folium sennae , Polygonum cuspidatum and so on, 8 herbals, Tong-fu-xing-shen. The intervention in this group includes po AICH-PXZY bid and the routine treatment of Western Medicine.Torn the medicine bag and take it after mixing with 50-80ml warm water(Or take by nasal feeding).

Removing Blood Stasis medicine without folium sennae and Snakegourd seed, 6 herbals, without the effect of Poxuezhuyu. The intervention in this group includes po AICH-without PXZY bid and the routine treatment of Western Medicine.Torn the medicine bag and take it after mixing with 50-80ml warm water(Or take by nasal feeding).

The placebo is made up of Starch, bitter taste and cyclodextrin. The intervention in this group includes po AICH-placebo bid and the routine treatment of Western Medicine.Torn the medicine bag and take it after mixing with 50-80ml warm water(Or take by nasal feeding).

Outcomes

Primary Outcome Measures

Hematoma enlargement
The hematoma volume enlarged 33% or increased 12.5ml defined as hematoma enlargement which are compared with the two CT scans(6-72h within onset and 24h after onset,or 6-72h within onset and 10-14days)

Secondary Outcome Measures

GCS scoring scale
The Glasgow score was used to assess the coma index.
National Institute of Health of stroke scale
The NIHSS is for evaluation of neurological deficits.
BI index
BI index <90 defines life cannot be independent. The percentage of BI 100-90 points in the three groups was statistically followed up by 90ds.
Social function activity questionnaire(FAQ)
FAQ is mainly to know the quality of life and living habits of the patients and their families.
fatality rate
Any cause of death within the entire treatment 10ds and follow-up 90ds.
modified rankin scale
Scoring 2-5 is defined as disability, which can be divided into 4 grades: mild, moderate, severe and severe. The percentage of mRS 0-1 points in the three groups will be statistically followed up by 90ds.

Full Information

First Posted
November 10, 2017
Last Updated
November 23, 2017
Sponsor
Guangzhou University of Traditional Chinese Medicine
Collaborators
Lianjiang people's Hospital, Shenyang Second Hospital of traditional Chinese Medicine, The Third People's Hospital of Hubei Province, Liaocheng People's Hospital, Zengcheng Hospital of traditional Chinese Medicine, Shouguang people's Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT03354026
Brief Title
Clinical Evaluation of Removing Blood Stasis Therapy in Treating Acute Cerebral Hemorrhage Safety and Efficacy
Acronym
CERBSTTSCH
Official Title
Clinical Evaluation of Removing Blood Stasis Therapy in Treating Acute Cerebral Hemorrhage Safety and Efficacy
Study Type
Interventional

2. Study Status

Record Verification Date
November 2017
Overall Recruitment Status
Unknown status
Study Start Date
November 2017 (Anticipated)
Primary Completion Date
December 2022 (Anticipated)
Study Completion Date
December 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Guangzhou University of Traditional Chinese Medicine
Collaborators
Lianjiang people's Hospital, Shenyang Second Hospital of traditional Chinese Medicine, The Third People's Hospital of Hubei Province, Liaocheng People's Hospital, Zengcheng Hospital of traditional Chinese Medicine, Shouguang people's Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this research is to use the "Removing Blood Stasis Decotion" of traditional Chinese medicine treating the acute stage of cerebral hemorrhage with stroke associated pneumonia to explore the impact of "Removing Blood Stasis Therapy" on intestinal microbial flora either within the time window from 6 to 72 hours onset.
Detailed Description
objective: to investigate the impact and immunologic mechanism of using the "Removing Blood Stasis Decotion" treatment in SAP after Acute Cerebral Hemorrhage with the concept of Intestinal Micro Ecological Regulation. Methods: from 2017.01 to 2022.12, 240 cases of AICH, 306 cases of hypertension will be included in 7 research centers. The AICH patients are randomly into 3 groups within 6 to 72hrs from onset, thus there are 3 groups and the treatment will last for 10 days: group A,Removing Blood Stasis herbal medicine(8 herbals); Group B, herbal medicine without Poxuezhuyu activating herbal(6 herbals); Group C, placebo medicine of Chinese medicine.All the patients will be treated according AHA guideline of AICH and will be set to the brain CT and chest X-ray at the onset, 24h later and 10-14days after treatment. The venous blood,feces Specimen and the sputum will be collected in the time point of 6 to 72hrs within onset , 24h later, and 10-14days after treatment.So the rate of enlargement of brain hematoma and the development of SAP in the 72h later, mortality rate in the two weeks and the disability rate in the 90 days can be evaluated.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Intracerebral Hemorrhage, Hypertensive, Traditional Chinese Medicine
Keywords
Blood-breaking Decotion

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
Our randomized program was completed by the key research laboratory of clinical research from the Traditional Chinese medicine Hospital of Guangdong Province. We design 306 cases into three groups: Group A, B, C in the proportion of 1:1:1. Group A is the experimental group used RBS, which include 8 herbals. Group B is the experimental group used PBS, which include all the herbals in Group A except Leech and Tabanus, rhubarb. Group C is a placebo group. This study adopts a stratified random sampling method and intra slice randomization on the basis of using PROC PLAN progress on SAS V9.2. On the other hand, this trial measures and the control measures will be made blind doubly. The surface of the opaque random envelopes will indicate the information of the test name, hospital name and the entry sequence number of patient. The research process of incorporating patient, dispensing medicine depending on the random envelopes and ect will all be supervised by the researchers each other.
Allocation
Randomized
Enrollment
306 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Experimental: AICH-PXZY
Arm Type
Experimental
Arm Description
Removing Blood Stasis medicine with folium sennae , Polygonum cuspidatum and so on, 8 herbals, Tong-fu-xing-shen. The intervention in this group includes po AICH-PXZY bid and the routine treatment of Western Medicine.Torn the medicine bag and take it after mixing with 50-80ml warm water(Or take by nasal feeding).
Arm Title
Experimental: AICH-without PXZY
Arm Type
Experimental
Arm Description
Removing Blood Stasis medicine without folium sennae and Snakegourd seed, 6 herbals, without the effect of Poxuezhuyu. The intervention in this group includes po AICH-without PXZY bid and the routine treatment of Western Medicine.Torn the medicine bag and take it after mixing with 50-80ml warm water(Or take by nasal feeding).
Arm Title
Placebo: AICH-placebo
Arm Type
Placebo Comparator
Arm Description
The placebo is made up of Starch, bitter taste and cyclodextrin. The intervention in this group includes po AICH-placebo bid and the routine treatment of Western Medicine.Torn the medicine bag and take it after mixing with 50-80ml warm water(Or take by nasal feeding).
Intervention Type
Drug
Intervention Name(s)
AICH-PXZY
Other Intervention Name(s)
herbal medicine with Hirudo, Tabanus
Intervention Description
8herbals (with 2 herbals of Activating blood stagnation and expelling blood stasis herbs) one dose, bid, for 10 days
Intervention Type
Drug
Intervention Name(s)
AICH-without PXZY
Other Intervention Name(s)
herbal medicine without Hirudo, Tabanus
Intervention Description
AICH-2(herbal medicine without Hirudo, Tabanus) (6herbals, without 2 herbals of promoting blood stasis) one dose, bid, for 10 days
Intervention Type
Drug
Intervention Name(s)
AICH-placebo
Other Intervention Name(s)
Placebo
Intervention Description
The placebo is made up of Starch, bitter taste and cyclodextrin
Primary Outcome Measure Information:
Title
Hematoma enlargement
Description
The hematoma volume enlarged 33% or increased 12.5ml defined as hematoma enlargement which are compared with the two CT scans(6-72h within onset and 24h after onset,or 6-72h within onset and 10-14days)
Time Frame
6-72h within onset, 24hrs, 10-14days
Secondary Outcome Measure Information:
Title
GCS scoring scale
Description
The Glasgow score was used to assess the coma index.
Time Frame
6-72hours within onset, 24hours later, 3 months
Title
National Institute of Health of stroke scale
Description
The NIHSS is for evaluation of neurological deficits.
Time Frame
6-72hours within onset, 24hours later, 3 months
Title
BI index
Description
BI index <90 defines life cannot be independent. The percentage of BI 100-90 points in the three groups was statistically followed up by 90ds.
Time Frame
3 months
Title
Social function activity questionnaire(FAQ)
Description
FAQ is mainly to know the quality of life and living habits of the patients and their families.
Time Frame
3 months
Title
fatality rate
Description
Any cause of death within the entire treatment 10ds and follow-up 90ds.
Time Frame
3 months
Title
modified rankin scale
Description
Scoring 2-5 is defined as disability, which can be divided into 4 grades: mild, moderate, severe and severe. The percentage of mRS 0-1 points in the three groups will be statistically followed up by 90ds.
Time Frame
3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Greater than or equal to 18 years old while younger than 80 years old acute cerebral hemorrhage confirmed by brain CT scan within 6 to72 hours from onset GCS≥6 Sign the informed consent form Exclusion Criteria: Tests have confirmed that cerebral hemorrhage caused by brain tumor, blood diseases, cerebrovascular malformation (anomaly) or aneurysm, etc; patients with Severe heart, liver and renal insufficiency. Intolerance to traditional Chinese medicine (TCM), allergic constitution. patients with severe cerebral hernia in the early onset Compliance is poor.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jianwen J Guo, Doctor
Phone
+86 13724899379
Email
jianwen_guo@qq.com
First Name & Middle Initial & Last Name or Official Title & Degree
Qixin Q Zhang, Master
Phone
+86 15626450556
Email
446763061@qq.com
Facility Information:
Facility Name
Guangdong Provincial Science and Technology Agency
City
Guangzhou
State/Province
Guangdong
ZIP/Postal Code
510033
Country
China
Facility Name
Guangdong Provincial Hospital of Chinese Medicine
City
Guangzhou
State/Province
Guangdong
ZIP/Postal Code
510120
Country
China

12. IPD Sharing Statement

Plan to Share IPD
Undecided
IPD Sharing Plan Description
We will keep the IPD in secret and share that only when the agreement are shown by the Ethics committee and the project committee,including the examination results, genotype, etc.
Citations:
PubMed Identifier
30224926
Citation
Zhang Q, Zeng L, Chen X, Zhou Y, Gong B, Li H, Guo J. Clinical Evaluation of Herbal Medicine (ICH-012) in Treating Acute Cerebral Haemorrhage: Safety and Efficacy from 6- to 72-Hour Time Window (CRRICHTrial-II). Evid Based Complement Alternat Med. 2018 Aug 26;2018:3120179. doi: 10.1155/2018/3120179. eCollection 2018.
Results Reference
derived

Learn more about this trial

Clinical Evaluation of Removing Blood Stasis Therapy in Treating Acute Cerebral Hemorrhage Safety and Efficacy

We'll reach out to this number within 24 hrs